Background: Very few studies using the combination of topical 8-methoxypsoralen (8-MOP) and narrow-band ultraviolet B (NBUVB) have been performed, especially in Indian patients. A combination of oral psoralen with NBUVB has been shown to have a superior efficacy as compared with NBUVB alone in psoriasis.
Aims: Comparison of the efficacy of topical psoralen NBUVB (combination) versus NBUVB alone in psoriasis.
Methods: Thirty patients with plaque psoriasis were taken up for the study and NBUVB phototherapy was given twice weekly. The target lesions on one side were treated with 0.1% topical 8-MOP 15 min before the irradiation. The treatment period was 12 weeks or 24 exposures.
Results: The number of treatment sessions and cumulative NBUVB doses were lower in the combination therapy as compared with NBUVB monotherapy, although the differences were not statistically significant.
Conclusion: To conclude, topical 8-MOP enhances the therapeutic effects of NBUVB therapy without increasing the incidence of adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0378-6323.72464 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NOD2 expression in psoriasis before and after treatment with Narrowband Ultraviolet B phototherapy.
Arch Dermatol Res
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Psoriasis is a chronic inflammatory skin condition characterized by hyperproliferation of keratinocytes and immune dysregulation. Narrow band ultraviolet B (NB-UVB) phototherapy is a common treatment for psoriasis due to its efficacy and safety profile. NOD2 is an intracellular pattern recognition receptor involved in immune responses and inflammation, and its expression is elevated in psoriatic skin.
View Article and Find Full Text PDFConcurrent management of vitiligo and acquired disorders of hyperpigmentation: a comprehensive literature review and current practice gaps.
Int J Dermatol
January 2025
Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Few studies discuss the co-management of vitiligo and acquired hyperpigmentation disorders (AHD) such as melasma, erythema dyschromicum perstans, post-inflammatory hyperpigmentation, drug-induced hyperpigmentation, and lichen planus pigmentosus. This review discusses clinical studies examining co-management strategies and identifies current practice gaps. Dermatology Life Quality Index scores are higher in individuals with vitiligo or melasma.
View Article and Find Full Text PDFFractional CO laser combined with narrow-band ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in vitiligo patients: prospective, self-controlled, and randomized trial.
Lasers Med Sci
January 2025
Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Vitiligo is a chronic depigmenting condition that causes amelanotic macules and patches on the skin. Despite various treatment options, treating vitiligo is a challenge. This study aimed to evaluate the combination of laser CO fractional and narrow-band ultraviolet B (NB-UVB) versus NB-UVB monotherapy in vitiligo patients.
View Article and Find Full Text PDFCombination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Background: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).
View Article and Find Full Text PDFTopical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society.
Clin Cosmet Investig Dermatol
December 2024
Consultant Dermatologist, Indore, Madhya Pradesh, India.
Background: Tacrolimus, a topical calcineurin inhibitor (TCI) with immunomodulatory effects, is considered a viable treatment option for vitiligo. A consensus building exercise was undertaken to determine the role and clinical utility of topical tacrolimus in the management of vitiligo using input from experts in the field of dermatology.
Methods: Seventeen experts collaborated to create consensus statements using a modified Delphi methodology.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!